Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore

News

Stay up to date on the latest crypto trends with our expert, in-depth coverage.

banner
All
Crypto
Stocks
Commodities & Forex
Macro
Flash
22:45
PDG, backed by Warburg Pincus, plans to raise $5 billion in debt to expand its data centers
The financing will be used for facility construction in India, Indonesia, Malaysia, and Japan. A consortium of banks will jointly undertake part of the loan. Supported by Warburg Pincus, PDG adopts a "future revenue-based collateral" model, which means borrowing against already signed customer contracts. The company has signed solid contracts with hyperscalers for periods of 10-12 years. Currently, the company operates artificial intelligence (AI) data centers in seven markets across Asia, with a total portfolio capacity exceeding 1.8 GW.
22:12
The three major U.S. stock indexes closed mixed.
Glonghui March 11|The three major US stock indexes closed mixed, with the Dow Jones down 0.07%, the Nasdaq up 0.01%, and the S&P 500 down 0.21%. The optical communication sector surged, with AAOI up nearly 9% and Lumentum up more than 4%. Memory-related stocks rose, with SanDisk up more than 5%, Micron Technology up more than 3%, and Western Digital up more than 1%. Paramount Global fell more than 7%, hitting a near two-week low.
21:53
According to the latest filing with the U.S. Securities and Exchange Commission, biotechnology company Rocket Pharmaceuticals, Inc. has officially signed an equity sales agreement with renowned financial institution Cantor Fitzgerald & Co.
The agreement involves an At-the-Market (ATM) offering program with a maximum financing scale of up to 100 million USD. This collaboration will grant Rocket Pharmaceuticals the flexibility to issue and sell common stock to Cantor Fitzgerald at appropriate times based on market conditions. The ATM issuance mechanism allows listed companies to raise capital in batches according to funding needs, effectively optimizing the timing of financing and reducing the impact on stock prices. As a clinical-stage company focused on developing gene therapies for rare diseases, this financing arrangement will provide significant funding support for Rocket Pharmaceuticals to advance its innovative therapy development pipeline. The details of this agreement have been filed with the U.S. Securities and Exchange Commission via Form 8-K.
News